Posted by Michael Wonder on 10 Jun 2022
Everest Medicines announces approval of Trodelvy in China for second-line metastatic triple negative breast cancer
10 June 2022 - Everest plans to launch commercial sales of Trodelvy in China in Q4, 2022.
Everest Medicines announced today that China's National Medical Products Administration has approved Trodelvy (sacituzumab govitecan) for the treatment of adult patients with unresectable locally advanced or metastatic triple negative breast cancer who have received two or more prior systemic therapies, at least one of them for metastatic disease.
